Converting IFCC to HbA1c percentage is a common need for patients and clinicians navigating between the two reporting systems used for this key diabetes blood test. HbA1c measures average blood glucose levels over two to three months and is central to diagnosing and managing diabetes in the UK. NHS laboratories now report results in IFCC units (mmol/mol), yet many patients remain familiar with the older NGSP percentage format. This article explains the validated conversion formula, a quick-reference table, why the NHS switched to IFCC units, and how to interpret your result against current NICE diagnostic and treatment thresholds.

Understanding HbA1c Units: IFCC and NGSP Explained

IFCC (mmol/mol) is the internationally standardised unit now used by the NHS, whilst NGSP (%) is the older DCCT-aligned percentage system still familiar to many patients diagnosed before 2011.

HbA1c is a blood test that measures the average level of glucose attached to haemoglobin over the preceding two to three months. It is a cornerstone investigation in both the diagnosis and ongoing management of diabetes mellitus. However, understanding your result can be confusing because HbA1c is reported using two different measurement systems, and patients may encounter both depending on when or where they were tested.

The two systems are:

• IFCC (International Federation of Clinical Chemistry and Laboratory Medicine): Reports HbA1c in millimoles per mole (mmol/mol). This is the internationally standardised reference method now used across the NHS and most of Europe.

• NGSP (National Glycohaemoglobin Standardisation Program): Reports HbA1c as a percentage (%). This system was aligned to the landmark DCCT (Diabetes Control and Complications Trial) and remains widely used in the United States and in older UK literature.

Both units reflect the proportion of haemoglobin molecules that have glucose bound to them — a process known as glycation. However, they use different mathematical scales and reference standards: the NGSP percentage is DCCT-aligned, whilst the IFCC value is derived from a more rigorously defined reference measurement procedure. Because many patients, particularly those diagnosed before 2011, are more familiar with the percentage figure, healthcare professionals and patients alike often need to convert between the two.

Understanding which unit your result is expressed in is the essential first step before interpreting any HbA1c value. The NHS HbA1c blood test page and Diabetes UK both provide plain-English explanations of units and results interpretation.

How to Convert IFCC (mmol/mol) to HbA1c (%)

Use the formula NGSP (%) = (0.0915 × IFCC) + 2.15; for example, 48 mmol/mol equals 6.5%, the UK diagnostic threshold for diabetes.

Converting between IFCC (mmol/mol) and NGSP (%) values is straightforward using a validated mathematical formula. The officially accepted conversion equations, derived from the IFCC–NGSP master equation and used in clinical practice, are as follows:

• IFCC to NGSP (%): NGSP (%) = (0.0915 × IFCC) + 2.15

• NGSP (%) to IFCC (mmol/mol): IFCC (mmol/mol) = (NGSP − 2.15) ÷ 0.0915

Please note that minor rounding differences of approximately 0.1% may occur between different calculators or laboratory systems due to analytical variability and rounding conventions.

For practical reference, some commonly encountered conversion values include:

| IFCC (mmol/mol) | NGSP (%) | |---|---| | 39 | 5.7 | | 42 | 6.0 | | 48 | 6.5 | | 53 | 7.0 | | 58 | 7.5 | | 64 | 8.0 | | 75 | 9.0 | | 86 | 10.0 |

Many NHS trusts and diabetes charities such as Diabetes UK provide online conversion calculators to make this process straightforward for patients and clinicians. It is important to always confirm which unit your laboratory report uses before attempting any conversion, as misinterpreting the unit could lead to significant errors in clinical decision-making. If you are ever uncertain about your result, your GP practice or diabetes care team can clarify the figure and explain what it means in the context of your individual health.

Why the NHS Changed to IFCC Units for HbA1c Reporting

The NHS adopted IFCC units (mmol/mol) by June 2011 to improve analytical precision, reduce inter-laboratory variability, and align with international standards.

Prior to 2009, UK laboratories reported HbA1c exclusively as a percentage using the NGSP system. However, a global standardisation initiative led by the IFCC resulted in a new, more precisely defined reference measurement procedure. The NHS began a phased transition to IFCC units (mmol/mol) from 2009, with full adoption completed by June 2011, in line with guidance from NHS England, the Association for Clinical Biochemistry (ACB), and the Royal College of Pathologists (RCPath). This change aligned the UK with international laboratory standards and improved the accuracy and comparability of results across different laboratories and countries.

The primary reasons for the change included:

• Greater analytical precision: The IFCC method is based on a more rigorously defined reference standard, reducing inter-laboratory variability.

• International harmonisation: Adopting a single global standard allows clinicians and researchers to compare results across different healthcare systems more reliably.

• Improved precision and comparability: The IFCC scale allows more consistent distinction of small but clinically meaningful differences in glycaemic control across laboratories.

The transition was carefully managed to minimise patient confusion. For a period, laboratories reported both units simultaneously, and guidance was issued by NHS England, the ACB, RCPath, and Diabetes UK to support both patients and clinicians through the change. Today, all NHS laboratories report HbA1c in mmol/mol as the primary unit, though many reports still include the NGSP percentage in parentheses for reference. Patients who were diagnosed or managed under the old system may still think in percentage terms, which is why understanding how to convert between IFCC and NGSP units remains a practically useful skill.

What Your HbA1c Result Means for Diabetes Diagnosis

An HbA1c of 48 mmol/mol (6.5%) or above on two occasions confirms diabetes; 42–47 mmol/mol (6.0–6.4%) indicates non-diabetic hyperglycaemia requiring lifestyle intervention.

HbA1c is used not only to monitor existing diabetes but also as a diagnostic tool in appropriate clinical circumstances. In the UK, NICE (NG28) and NHS guidelines define specific thresholds that guide clinical interpretation. Understanding these thresholds helps patients make sense of their results and engage meaningfully with their healthcare team.

The key diagnostic thresholds are:

• Below 42 mmol/mol (6.0%): Normal range — diabetes is unlikely.

• 42–47 mmol/mol (6.0–6.4%): Indicates non-diabetic hyperglycaemia (sometimes referred to as prediabetes). This is a high-risk category where lifestyle intervention is strongly recommended to prevent progression to type 2 diabetes.

• 48 mmol/mol (6.5%) or above: Diagnostic of diabetes in the absence of symptoms, provided the result is confirmed by a repeat test on a separate occasion.

It is important to note that HbA1c is not appropriate for diagnosing diabetes in all circumstances. It should not be used as a diagnostic test in:

• Children and young people

• Pregnant women

• Individuals with haemoglobin variants (e.g., sickle cell trait or disease) or conditions affecting red blood cell turnover, including haemolytic anaemia, iron deficiency anaemia, recent blood transfusion, chronic kidney disease (stage 4–5), or erythropoietin (EPO) therapy

• Those with symptoms suggesting acute-onset or type 1 diabetes

In these situations, fasting plasma glucose or an oral glucose tolerance test (OGTT) is preferred, as HbA1c results may be falsely low or high and therefore unreliable.

Important — suspected type 1 diabetes or diabetic ketoacidosis (DKA): If you or someone you know experiences rapid unintentional weight loss, excessive thirst, frequent urination, abdominal pain, vomiting, or drowsiness, seek same-day urgent medical assessment. These may be symptoms of type 1 diabetes or DKA, which require immediate clinical evaluation. HbA1c should not be used to diagnose diabetes in this context.

Not sure if this is normal? Chat with one of our pharmacists →

If your HbA1c result falls in the non-diabetic hyperglycaemia range, your GP may recommend dietary changes, increased physical activity, and referral to the NHS Diabetes Prevention Programme. A result at or above 48 mmol/mol on two separate occasions (in an asymptomatic individual where HbA1c is appropriate) will typically prompt a formal diabetes diagnosis and initiation of a structured management plan.

NICE Guidelines on HbA1c Targets for Type 1 and Type 2 Diabetes

NICE recommends an HbA1c target of 48 mmol/mol (6.5%) for most adults with diabetes, rising to 53 mmol/mol (7.0%) when hypoglycaemia risk is present.

Once a diagnosis of diabetes is established, HbA1c monitoring becomes central to ongoing management. NICE provides clear, evidence-based targets to guide treatment decisions, balancing the benefits of tight glycaemic control against the risks of hypoglycaemia and treatment burden.

For type 2 diabetes (NICE NG28):

• A target of 48 mmol/mol (6.5%) is recommended for adults managed by lifestyle intervention or a single non-hypoglycaemic drug.

• If the person is on a drug associated with hypoglycaemia (e.g., a sulphonylurea or insulin), the target is relaxed to 53 mmol/mol (7.0%) to reduce hypoglycaemia risk.

• Individualised targets may be appropriate for older adults or those with significant comorbidities, frailty, or limited life expectancy.

For type 1 diabetes (NICE NG17):

• NICE recommends a target of 48 mmol/mol (6.5%) if achievable without problematic hypoglycaemia.

• Adults who are at risk of hypoglycaemia or who have impaired hypoglycaemia awareness may have a higher agreed target.

• Continuous glucose monitoring (CGM) and time-in-range metrics are increasingly used alongside HbA1c to provide a fuller picture of glycaemic control.

HbA1c should typically be measured every three to six months when treatment is being adjusted, and every six months once stable. Patients are encouraged to contact their GP or diabetes nurse if their HbA1c is consistently above their agreed target, or if they experience frequent hypoglycaemic episodes or have concerns about their medication.

Reporting suspected side effects: If you experience a suspected adverse reaction to your diabetes medication — such as hypoglycaemia with a sulphonylurea or insulin — this can be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Your GP or pharmacist can also assist with this.

Experiencing these side effects? Our pharmacists can help you navigate them →

Regular review ensures that treatment remains appropriate, safe, and aligned with the individual's overall health goals.

Frequently Asked Questions